Annals of Case Reports and Clinical Studies (ISSN: 2834-5673) | Volume 3, Issue 2 | Case Report | Open Access DOI
Deborah Cosentini*
Laganà M1, Cosentini D1*, Di Mauro P1, Laini L1, Schivardi G1, Ippolito G1, Richielmi L1, Vassalli L1,2, E.L Simoncini EL2, Grisanti S1, Pedersini R1,2, Berruti A1
1Department of Medical and Surgical Specialties, University of Brescia, Italy
2Breast Unit, University of Brescia, Italy
*Correspondence to: Deborah Cosentini
Fulltext PDFPatients with metastatic Triple-Negative Breast Cancer (TNBC) have a poor prognosis [1]. Sacituzumab Govitecan (SG) is an antibody-drug conjugate that contains the irinotecan active metabolite, SN-38, linked to a humanized monoclonal antibody targeting trophoblast cell surface antigen [2], which is overexpressed in many solid tumors and approximately in 90% of TNBC [2,3]. S.G demonstrated in a basket design phase I/II study [4], promising activity in multiple cancer cohorts and in international, multicenter phase 3 ASCENT trial a significant improvement of S.G over single-agent chemotherapies (capecitabine, gemcitabine, vinorelbine, eribulin) with respect to overall response rate (35% vs 5%), progression free survival (median 5.6 vs 1.7 months; Hazard Ratio [HR], 0.41; p < 0.001) and overall survival (median 12.1 vs 6.7 months; HR 0.48; p < 0.001) in TNBC patients who had received at least two chemotherapy regimens for advanced disease [5]. Key SG Treatment-Related Adverse Events (TRAEs) of grade ≥ 3 included neutropenia and diarrhea, that are toxicities attributable to its cytotoxic payload, SN-38 an active metabolite of irinotecan. A recent published sub-analysis demonstrated that SG has a manageable safety profile even in patients ≥ 65 years [6]. However, limited data are available in elderly patients because in ASCENT trial only 49 pts were older than 65 and 8 pts were older than 75 years. In addition, no real-world experiences in elderly patients have been published. This case report tried to share what we learn about diarrhea and hypocalcemia due to S.G in a metastatic TNBC, highly pretreated older patient in order to recognize earlier and to manage severe adverse events optimizing S.G treatment.
Breast cancer; Toxicity; Triple negative; Highly pretreated; Sacituzumab govitecan; Hypocalcemia; Diarrhea; Elderly patient
Laganà M, Cosentini D, Di Mauro P, Laini L, Schivardi G, Ippolito G, et al.Severe Hypocalcemia due to Sacituzumab Govitecan in Highly Pretreated Triple Negative Breast Cancer Old Patient.Ann Case RepClinStud.2024;3(2):1-8.